Browse our anti-Ret Proto-Oncogene (RET) Antibodies

Full name:
anti-Ret Proto-Oncogene Antibodies (RET)
On are 382 Ret Proto-Oncogene (RET) Antibodies from 24 different suppliers available. Additionally we are shipping Ret Proto-Oncogene Proteins (33) and Ret Proto-Oncogene Kits (18) and many more products for this protein. A total of 453 Ret Proto-Oncogene products are currently listed.
c-Ret, CDHF12, CDHR16, cret, etID315074.13, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET, ret-A, RET-ELE1, ret1, RET9, RET51, wu:fd13h01, X-ret, xret
list all antibodies Gene Name GeneID UniProt
RET 5979 P07949
RET 19713 P35546
RET 24716  

Show all species

Show all synonyms

Most Popular Reactivities for anti-Ret Proto-Oncogene (RET) Antibodies

Select your species and application

anti-Human Ret Proto-Oncogene Antibodies:

anti-Mouse (Murine) Ret Proto-Oncogene Antibodies:

anti-Rat (Rattus) Ret Proto-Oncogene Antibodies:

All available anti-Ret Proto-Oncogene Antibodies

Go to our pre-filtered search.

Top referenced anti-Ret Proto-Oncogene Antibodies

  1. Human Polyclonal Ret Proto-Oncogene Primary Antibody for EIA, FACS - ABIN359926 : Da Silva, Maciel, Da Silva, Toledo, De Carvalho, Cerutti: A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. in The Journal of clinical endocrinology and metabolism 2003 (PubMed)
    Show all 4 references for 359926

  2. Human Monoclonal Ret Proto-Oncogene Primary Antibody for IHC (p) - ABIN115113 : Nosrat, Tomac, Hoffer, Olson: Cellular and developmental patterns of expression of Ret and glial cell line-derived neurotrophic factor receptor alpha mRNAs. in Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 1997 (PubMed)
    Show all 3 references for 115113

  3. Human Monoclonal Ret Proto-Oncogene Primary Antibody for IF, IHC (p) - ABIN659065 : Siqueira, Romitti, da Rocha, Ceolin, Meotti, Estivalet, Puñales, Maia: The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma. in Endocrine-related cancer 2010 (PubMed)
    Show all 3 references for 659065

  4. Human Polyclonal Ret Proto-Oncogene Primary Antibody for ELISA, WB - ABIN1531387 : Takahashi, Buma, Hiai: Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. in Oncogene 1989 (PubMed)
    Show all 2 references for 1531387

  5. Human Monoclonal Ret Proto-Oncogene Primary Antibody for FACS, WB - ABIN4900140 : Fonseca-Pereira, Arroz-Madeira, Rodrigues-Campos, Barbosa, Domingues, Bento, Almeida, Ribeiro, Potocnik, Enomoto, Veiga-Fernandes: The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function. in Nature 2014 (PubMed)
    Show all 2 references for 4900140

  6. Human Monoclonal Ret Proto-Oncogene Primary Antibody for IHC (p), IHC - ABIN269684 : Barrenschee, Böttner, Hellwig, Harde, Egberts, Becker, Wedel: Site-specific gene expression and localization of growth factor ligand receptors RET, GFRα1 and GFRα2 in human adult colon. in Cell and tissue research 2013 (PubMed)

  7. Human Monoclonal Ret Proto-Oncogene Primary Antibody for FACS - ABIN4897243 : Ibiza, García-Cassani, Ribeiro, Carvalho, Almeida, Marques, Misic, Bartow-McKenney, Larson, Pavan, Eberl, Grice, Veiga-Fernandes: Glial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence. in Nature 2016 (PubMed)

  8. Human Polyclonal Ret Proto-Oncogene Primary Antibody for IHC (p), WB - ABIN392041 : de Martimprey, Bertrand, Fusco, Santoro, Couvreur, Vauthier, Malvy: siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. in Nucleic acids research 2008 (PubMed)

  9. Human Polyclonal Ret Proto-Oncogene Primary Antibody for IHC (p), WB - ABIN392038 : Takaki, Nakayama, Misawa, Nakagawa, Kuniyasu: In vitro formation of enteric neural network structure in a gut-like organ differentiated from mouse embryonic stem cells. in Stem cells (Dayton, Ohio) 2006 (PubMed)

More Antibodies against Ret Proto-Oncogene Interaction Partners

Zebrafish Ret Proto-Oncogene (RET) interaction partners

  1. These data provide the first evidence for a physiologic role of these isoforms in RET pathway function.

  2. Significantly, we show that introduction of mapk10 (show MAPK10 Antibodies) mutations into ret heterozygotes enhanced the ENS deficit, supporting MAPK10 (show MAPK10 Antibodies) as a Hirschsprung disease (HSCR (show EDNRB Antibodies)) susceptibility locus. Our studies demonstrate that ret heterozygous zebrafish is a sensitized model, with many significant advantages over existing murine models, to explore the pathophysiology and complex genetics of HSCR (show EDNRB Antibodies).

  3. RET expression is investigated within the brain of zebrafish; both RET protein and mRNA are observed.

  4. In animals lacking Ret or Gfra3 (show GFRA3 Antibodies) function, myogenic gene expression is reduced in forming opercular muscles, but not in non-opercular muscles derived from the same muscle anlagen.

  5. evaluation of noncoding sequences at the zebrafish ret locus conserved among teleosts, and at the human RET locus, conserved among mammals

  6. genes beyond RET may be implicated in the genesis of sporadic cases of HD

Human Ret Proto-Oncogene (RET) interaction partners

  1. Up-regulation of RET expression is associated with medullary thyroid carcinoma.

  2. Eight rare RET-coding variants, one possible splice-site variant were identified in patients with Hirschsprung disease. Almost half of the identified rare variants are proven pathogenic in vitro.

  3. We also demonstrate that the effects of RET and NRG1 (show NRG1 Antibodies) are universal across European and Asian ancestries. In contrast, we detected a European-specific association of a low-frequency variant, rs80227144, in SEMA3. Conditional analyses on the lead SNPs revealed a secondary association signal, corresponding to an Asian-specific, low-frequency missense variant encoding RET p.Asp489Asn

  4. RET plays a role in mediating the phosphorylation of EGFR (show EGFR Antibodies) in head and neck squamous cell carcinoma. RET inhibition not only decreases tumor growth but also enhances the efficacy of EGFR (show EGFR Antibodies) inhibition with erlotinib treatment.

  5. Study identified TP53 (show TP53 Antibodies) and RET among the most mutated oncogenes in hepatocellular carcinoma to be associated with lower overall survival.

  6. A p.C634W mutation in ret proto-oncogene protein (RET) has been detected in a family affected with multiple endocrine neoplasia type 2A (MEN2A), in which most carriers have developed clinical symptoms.

  7. RET/papillary thyroid cancer (PTC (show F9 Antibodies)) rearrangements, resulting in aberrant activity of the RET protein tyrosine kinase (show EPHA8 Antibodies) receptor (show NTRK1 Antibodies), occur exclusively in papillary thyroid cancer. Serum thyroid stimulating hormone in RET/PTC-positive thyroid cancer patients without nodular goiter or Hashimoto's thyroiditis increased following surgery.

  8. RET aberrations were seen in 1.8% of diverse cancers, with most cases harboring actionable, albeit distinct, coexisting alterations

  9. RET is overexpressed in only a small subset of oral squamous cell carcinomas

  10. RET rs2435357 variant is a genetic risk for Hirschsprung disease in Indonesia.

Mouse (Murine) Ret Proto-Oncogene (RET) interaction partners

  1. we described a RET-ER81 (show ETV1 Antibodies)-Neuregulin1 signaling pathway in neurons innervating Pacinian corpuscle somatosensory end organs, which is essential for communication between the innervating axon and the end organ

  2. These data provide the first evidence for a physiologic role of these isoforms in RET pathway function.

  3. Hox (show MSH2 Antibodies) proteins coordinate motor neuron differentiation and connectivity programs through Ret/Gfra genes.

  4. Ret and Gfra2 (show GFRA2 Antibodies) null mice display comparable early central projection deficits, but Gfra2 (show GFRA2 Antibodies) null rapidly adapting mechanoreceptors recover later.

  5. Parkin (show PARK2 Antibodies) and the RET signaling cascade converge to control mitochondrial integrity and thereby properly maintain substantia nigra pars (show EPRS Antibodies) compacta dopaminergic neurons and their innervation in the striatum.

  6. the Ret signaling pathway is important for podocyte survival and recovery from glomerular injury in vivo

  7. RET coupling to ERK (show EPHB2 Antibodies) and Akt (show AKT1 Antibodies) depends strongly on artemin (show ARTN Antibodies) concentration, and it is highest at the low (~100 pM) artemin (show ARTN Antibodies) levels required for neurite outgrowth.

  8. we analysed non-thermal, atmospheric pressure, plasma irradiation mediated effects in melanocytic tumors which spontaneously developed in HL-RET-mice

  9. the important IL-10 (show IL10 Antibodies) transcription factor Maf (show MAF Antibodies) was upregulated in RET-deficient Th2 cells and down-regulated upon RET signalling activation by glial-derived neurotrophic factor (show NTF3 Antibodies) family ligands.

  10. the neurotrophic factor (show NTF3 Antibodies) receptor RET drives haematopoietic stem cell survival, expansion and function; haematopoietic stem cells express RET and its neurotrophic factor (show NTF3 Antibodies) partners are produced in the haematopoietic stem cell environment

Ret Proto-Oncogene (RET) Antigen Profile

Antigen Summary

This gene, a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their biological validity has not been confirmed.

Alternative names and synonyms associated with Ret Proto-Oncogene (RET)

  • ret proto-oncogene receptor tyrosine kinase (ret) antibody
  • ret proto-oncogene (ret) antibody
  • ret proto-oncogene (RET) antibody
  • ret proto-oncogene (Ret) antibody
  • c-Ret antibody
  • CDHF12 antibody
  • CDHR16 antibody
  • cret antibody
  • etID315074.13 antibody
  • HSCR1 antibody
  • MEN2A antibody
  • MEN2B antibody
  • MTC1 antibody
  • PTC antibody
  • RET antibody
  • ret-A antibody
  • RET-ELE1 antibody
  • ret1 antibody
  • RET9 antibody
  • RET51 antibody
  • wu:fd13h01 antibody
  • X-ret antibody
  • xret antibody

Protein level used designations for RET

proto-oncogene tyrosine-protein kinase receptor Ret , receptor tyrosine kinase , ret proto-oncogene , tryptase , proto-oncogene tyrosine-protein kinase receptor Ret-like , RET transforming sequence , cadherin family member 12 , cadherin-related family member 16 , hydroxyaryl-protein kinase , proto-oncogene c-Ret , ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease) , Ret gene for receptor tyrosin , Ret proto-oncogene (multiple endocrine neoplasia MEN2A MEN2B and medullary thyroid carcinoma 1 Hirschsprung disease) , ret tyrosine kinase

30512 Danio rerio
373625 Xenopus laevis
449594 Pan troglodytes
703466 Macaca mulatta
100033966 Equus caballus
100403596 Callithrix jacchus
100442682 Pongo abelii
100467317 Ailuropoda melanoleuca
100495902 Xenopus (Silurana) tropicalis
100602103 Nomascus leucogenys
5979 Homo sapiens
19713 Mus musculus
24716 Rattus norvegicus
403494 Canis lupus familiaris
396107 Gallus gallus
515924 Bos taurus
100340710 Oryctolagus cuniculus
100733392 Cavia porcellus
Selected quality suppliers for anti-Ret Proto-Oncogene (RET) Antibodies
Did you look for something else?